Xarelto may be alternative for cancer patients with VTE

Patients with cancer who have had venous thromboembolism may have lower risk of bleeding with XARELTO® (rivaroxaban) , a study in Lancet Haematology suggests

FDA approves new anti-clotting drug for use after hip and knee replacements

The Food and Drug Administration has approved a new oral anticoagulant that helps prevent deep vein thrombosis in people recovering from knee or hip replacements.